Antibiotic Drug Discovery
New Targets and Molecular Entities
Herausgeber: Firestine, Steven M; Lister, Troy
Antibiotic Drug Discovery
New Targets and Molecular Entities
Herausgeber: Firestine, Steven M; Lister, Troy
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book identifies and elaborates the most recent and compelling strategies for antibiotic drug discovery with a primary focus on new targets, mechanisms and molecular entities.
Andere Kunden interessierten sich auch für
- Laura Bowater (UK University of East Anglia)Microbes Fight Back35,99 €
- Epigenetics for Drug Discovery221,99 €
- Lee KnowMitochondria and the Future of Medicine26,99 €
- Food Industry 4.0136,99 €
- Zoonoses95,99 €
- Accounts in Drug Discovery168,99 €
- Drug Repurposing207,99 €
-
-
-
This book identifies and elaborates the most recent and compelling strategies for antibiotic drug discovery with a primary focus on new targets, mechanisms and molecular entities.
Produktdetails
- Produktdetails
- Drug Discovery
- Verlag: Royal Society of Chemistry
- Seitenzahl: 286
- Erscheinungstermin: 30. Mai 2017
- Englisch
- Abmessung: 236mm x 160mm x 20mm
- Gewicht: 588g
- ISBN-13: 9781782624240
- ISBN-10: 1782624244
- Artikelnr.: 47367939
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Drug Discovery
- Verlag: Royal Society of Chemistry
- Seitenzahl: 286
- Erscheinungstermin: 30. Mai 2017
- Englisch
- Abmessung: 236mm x 160mm x 20mm
- Gewicht: 588g
- ISBN-13: 9781782624240
- ISBN-10: 1782624244
- Artikelnr.: 47367939
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Steven M. Firestine is an Associate Professor of Medicinal Chemistry at the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University. He received a B.S. with honors in chemistry from the University of Michigan and a PhD in Medicinal Chemistry from Purdue University. Dr. Firestine conducted postdoctoral research in the laboratory of Dr. Stephen J. Benkovic before joining the medicinal chemistry faculty at Duquesne University. In 2005 he moved to Wayne State University. Dr. Firestine maintains an active research program focused in the area of anti-infective drug design. To date, he has authored more than 40 articles in peer-reviewed research journals and presented more than 75 research abstracts and seminars. Dr. Firestine is an active reviewer for the NIH and the MRC. He serves on the editorial board of ACS Combinatorial Sciences and is a reviewer for numerous scientific journals. Troy Lister, PhD, is Head of Chemistry at Spero Therapeutics in Cambridge, MA. Dr. Lister previously held roles as Team Leader of Infection Chemistry at AstraZeneca and Investigator III in Global Discovery Chemistry at the Novartis Institute for BioMedical Research. He has lead numerous discovery programs searching for novel agents targeting bacterial and viral pathogens including multidrug resistant Gram negative and Gram positive bacteria, hepatitis C virus, human rhinovirus, respiratory syncytial virus, ebola virus and human enterovirus. Dr. Lister has led programs from the earliest stages of target selection and high throughput screening, through lead identification and optimization, to candidate selection and IND enablement. He is an author of 15 peer review publications, has extensive experience in natural product chemistry and is a member of the American Chemical Society. Dr. Lister received his B.Tech, B.S. and PhD degrees from Flinders University in Adelaide, Australia, and completed a post-doctoral fellowship at The Scripps Research Institute in La Jolla, California with Professoer K.C. Nicolaou.
Treatment of Clostridium difficile Infections
Targeting Purine Biosynthesis for Antibacterial Drug Design
Inhibitors of Biofilm Production
Narrow Spectrum Antibacterial Agents
The LPS Transport Pathway: A New Target for the Development of Gram-Negative Antibiotics
The Discovery of Teixobactin
Emerging Targets in Anti-Tubercular Drug Design
Antibacterial Leads Targeting Isoprenoid Biosynthesis
Targeting Purine Biosynthesis for Antibacterial Drug Design
Inhibitors of Biofilm Production
Narrow Spectrum Antibacterial Agents
The LPS Transport Pathway: A New Target for the Development of Gram-Negative Antibiotics
The Discovery of Teixobactin
Emerging Targets in Anti-Tubercular Drug Design
Antibacterial Leads Targeting Isoprenoid Biosynthesis
Treatment of Clostridium difficile Infections
Targeting Purine Biosynthesis for Antibacterial Drug Design
Inhibitors of Biofilm Production
Narrow Spectrum Antibacterial Agents
The LPS Transport Pathway: A New Target for the Development of Gram-Negative Antibiotics
The Discovery of Teixobactin
Emerging Targets in Anti-Tubercular Drug Design
Antibacterial Leads Targeting Isoprenoid Biosynthesis
Targeting Purine Biosynthesis for Antibacterial Drug Design
Inhibitors of Biofilm Production
Narrow Spectrum Antibacterial Agents
The LPS Transport Pathway: A New Target for the Development of Gram-Negative Antibiotics
The Discovery of Teixobactin
Emerging Targets in Anti-Tubercular Drug Design
Antibacterial Leads Targeting Isoprenoid Biosynthesis